These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 10848375)
1. Drug treatments for schizophrenia. Adams C; Wilson P; Gilbody S; Bagnall AM; Lewis R Qual Health Care; 2000 Mar; 9(1):73-9. PubMed ID: 10848375 [No Abstract] [Full Text] [Related]
2. [Expensive but nevertheless cost effect? Pharmacoeconomics of atypical neuroleptics]. Laux G; Günther W Pharm Unserer Zeit; 2002; 31(6):572-6. PubMed ID: 12481515 [No Abstract] [Full Text] [Related]
4. Antipsychotic drugs: the costs and benefits. Harv Ment Health Lett; 2007 Mar; 23(9):5-6. PubMed ID: 17390404 [No Abstract] [Full Text] [Related]
5. [The contribution of clinical pharmacy: optimization of administration in schizophrenic disorders]. Reinbold H Pharm Unserer Zeit; 2002; 31(6):566-71. PubMed ID: 12481514 [No Abstract] [Full Text] [Related]
6. Cost-effectiveness of schizophrenia pharmacotherapy. Soumerai SB; Law MR Am J Psychiatry; 2007 Apr; 164(4):678; author reply 678-9. PubMed ID: 17403984 [No Abstract] [Full Text] [Related]
7. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. Revicki DA J Psychiatry Neurosci; 1997 Jul; 22(4):256-66. PubMed ID: 9262048 [TBL] [Abstract][Full Text] [Related]
8. Delaying time to relapse in schizophrenia. The role of long-acting injectable antipsychotics. Muller R Manag Care; 2014 Apr; 23(4 Suppl 1):2-3. PubMed ID: 25029779 [No Abstract] [Full Text] [Related]
9. The NIMH-CATIE Schizophrenia Study: what did we learn? Lieberman JA; Stroup TS Am J Psychiatry; 2011 Aug; 168(8):770-5. PubMed ID: 21813492 [No Abstract] [Full Text] [Related]
10. Which atypical antipsychotic. Thomas CS; Lewis S Br J Psychiatry; 1998 Feb; 172():106-9. PubMed ID: 9519061 [No Abstract] [Full Text] [Related]
11. Trial that pays patients to take antipsychotic drugs comes under attack. Eaton L BMJ; 2009 Oct; 339():b4202. PubMed ID: 19822620 [No Abstract] [Full Text] [Related]
14. [Cost analysis of the strategies in the treatment of schizophrenics: the place of sustained release injectable atypical antipsychotics]. Gasquet I; Bouhassira M; Launois R Encephale; 2005; 31(4 Pt 1):517-8. PubMed ID: 16389719 [No Abstract] [Full Text] [Related]
16. Polypharmacy in schizophrenia: a fuzzy concept. Freudenreich O; Goff DC J Clin Psychiatry; 2003 Sep; 64(9):1132; author reply 1132-3. PubMed ID: 14628993 [No Abstract] [Full Text] [Related]
17. Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Citrome L Int J Clin Pract; 2010 Jan; 64(2):216-39. PubMed ID: 19886879 [TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us? Annemans L Pharmacoeconomics; 2005; 23 Suppl 1():1-2. PubMed ID: 16416757 [No Abstract] [Full Text] [Related]
19. Treatment of schizophrenia: let's talk dollars and sense. Buckley PF Am J Manag Care; 1998 Mar; 4(3):369-83. PubMed ID: 10178499 [TBL] [Abstract][Full Text] [Related]
20. Effects of capitation on health of the chronically ill. Implications for antipsychotic drug therapy. Reed SK; Maharaj K Pharmacoeconomics; 1994 Dec; 6(6):506-12. PubMed ID: 10155280 [No Abstract] [Full Text] [Related] [Next] [New Search]